Navigation Links
Reportlinker Adds U.S. Retinal Therapeutics Market
Date:6/22/2011

NEW YORK, June 22, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

U.S. Retinal Therapeutics Market

http://www.reportlinker.com/p0559274/US-Retinal-Therapeutics-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment

This research service provides an indepth analysis of factors affecting the growth of the U.S. retinal therapeutics market over the period 2006-2016. Included are disease and treatment overviews, product analyses, patient forecasts, product revenue forecasts, and market share analyses. In this research service, the market is segmented by retinal disease: age-related macular degeneration (AMD), diabetic retinopathy (DR)/diabetic macular edema (DME), and both branch and central retinal vein occlusion (BRVO/CRVO). Major market challenges, drivers, and restraints are identified and discussed. Additionally, a pipeline of compounds making their way through clinical trials is presented in the "Product Pipeline" section of this research service.

Table of Contents

C h a p t e r 1

Executive Summary

U.S. Retinal Therapeutics Market 1-1

Introduction 1-1

C h a p t e r 5

Appendix

Decision Support Databases 1-1

Total Population 1-1

Population Aged 15 to 24 Years 1-3

Population Aged 25 to 34 Years 1-5

Population Aged 35 to 44 Years 1-7

Population Aged 45 to 54 Years 1-9

Population Aged 55 to 64 Years 1-11

Population Above 45 Years 1-13

Population Above 65 Years 1-15

AMD Prevalence 1-17

AMD Incidence 1-20

Diabetes Prevalence 1-22

Diabetes Incidence 1-24

C h a p t e r 4

Market Analysis

Market Outlook and Revenue Forecasts 1-1

Age-related Macular Degeneration 1-1

WET AMD 1-1

Diabetic Retinopathy and Diabetic Macular Edema 1-18

ANTI-VEGFs 1-19

CORTICOSTEROIDS 1-24

OTHER LATE-STAGE CANDIDATES 1-33

Retinal Vein Occlusion 1-34

CORTICOSTEROIDS 1-34

ANTI-VEGFs 1-35

VEGF Trap-Eye 1-36

Competitive Overview 1-37

Competitive Structure 1-37

C h a p t e r 3

Treatment Overview and Product Pipeline

Treatment Overview 1-1

Age-Related Macular Degeneration 1-1

Product Analysis and Treatment Practices for AMD 1-1

Visudyne (Verteporfin) 1-1

Macugen (Pegaptanib) 1-2

Lucentis (Ranibizumab) 1-2

Avastin (Bevacizumab) 1-3

Other Treatment Practices 1-3

Diabetic Retinopathy and Diabetic Macular Edema 1-4

Current Treatments and Practices for Diabetic Retinopathy 1-4

Current Treatments and Practices for Diabetic Macular Edema 1-4

Retinal Vein Occlusion 1-5

Product Pipeline 1-6

Age-Related Macular Degeneration 1-6

Diabetic Retinopathy and Diabetic Macular Edema 1-8

Retinal Vein Occlusion 1-9

C h a p t e r 2

Market Introduction

Research Scope and Methodology 1-1

Scope and Segmentation 1-1

Research Methodology 1-2

Market Overview 1-2

Introduction 1-2

Disease Overviews 1-3

Age-Related Macular Degeneration 1-3

Diabetic Retinopathy and Diabetic Macular Edema 1-4

Retinal Vein Occlusion 1-5

Clinical Need and Burden of Disease 1-5

Age-related Macular Degeneration 1-5

Wet and Dry AMD Prevalence 1-5

Wet AMD Treated Patient Forecast 1-8

Diabetic Retinopathy and Diabetic Macular Edema 1-10

Diabetic Retinopathy 1-10

Diabetic Macular Edema 1-12

Retinal Vein Occlusion 1-13

Prevalence Rates: RVO, BRVO and CRVO 1-13

Treatable Patient Population 1-15

Market Trends 1-16

Market Engineering Measurements 1-16

Industry Challenges and Strategies 1-17

Off-Label Use of Avastin Significantly Suppresses Revenue Potential 1-18

Lengthy and Costly Clinical Trials Impede New Market Entrants 1-19

Developing Therapies to Treat Diseases of the Back-of-the-Eye is Complex 1-19

Established Treatment Alternatives Impede Success of New DME Therapies 1-19

Market Drivers 1-20

Worldwide Diabetes Epidemic Fuels Research into Vision-Compromising Comorbidities 1-20

Presence of Novel Biopharmaceuticals Boosts Market 1-21

Market Opportunity for Wet AMD Drugs Further Expanded by Penetration into other

Highly Lucrative Back-of-the-Eye Diseases 1-21

Advancements in Formulation Technology Opens New Routes to Revenue Generation 1-21

Aging Population to Significantly Increase Demand for Treatment 1-22

List of Figures

C h a p t e r 2

Market Introduction

2-1 Retinal Therapeutics Market:

Intermediate AMD and Advanced Dry AMD Prevalence Forecasts (U.S.), 2006-2016 1-6

2-2 Retinal Therapeutics Market:

Wet AMD Prevalence Forecast (U.S.), 2006-2016 1-7

2-3 Retinal Therapeutics Market:

Wet AMD Treated Patient Forecast (U.S.), 2006-2016 1-9

2-4 Retinal Therapeutics Market:

DR Prevalence Forecasts among All Diabetics and among Type I

Diabetics (U.S.), 2006-2016 1-11

2-5 Retinal Therapeutics Market:

Incidence and Treated Patient Forecasts for DME among Diagnosed

Diabetics (U.S.), 2006-2016 1-12

2-6 Retinal Therapeutics Market:

CRVO, BRVO, and Total RVO Prevalence Forecasts (U.S.), 2006-2016 1-14

2-7 Retinal Therapeutics Market:

BRVO, CRVO, and Total RVO Treatment-Eligible Patient Forecasts (U.S.), 2006-2016 1-15

2-8 Retinal Therapeutics Market:

Top Four Industry Challenges Ranked in Order of Impact (U.S.), 2011-2016 1-18

2-9 Retinal Therapeutics Market:

Market Drivers Ranked in Order of Impact (U.S.), 2011-2016 1-20

C h a p t e r 3

Treatment Overview and Product Pipeline

3-1 Retinal Therapeutics Market:

Wet AMD Pipeline Overview (U.S.), 2010 1-7

3-2 Retinal Therapeutics Market:

Dry AMD Pipeline Overview (U.S.), 2010 1-8

3-3 Retinal Therapeutics Market:

DR and DME Pipeline Overview (U.S.), 2010 1-9

3-4 Retinal Therapeutics Market:

RVO Pipeline Overview (U.S.), 2010 1-9

C h a p t e r 4

Market Analysis

4-1 Retinal Therapeutics Market:

Visudyne Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-2

4-2 Retinal Therapeutics Market:

Macugen Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-4

4-3 Retinal Therapeutics Market:

Product Market Share by Revenue - AMD Segment (U.S.), 2009 1-6

4-4 Retinal Therapeutics Market:

Product Market Share by Patients - AMD Segment (U.S.), 2009 1-7

4-5 Retinal Therapeutics Market:

VEGF Trap-EYE Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-10

4-6 Retinal Therapeutics Market:

Lucentis Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-12

4-7 Retinal Therapeutics Market:

Avastin Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-13

4-8 Retinal Therapeutics Market:

Total AMD Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-15

4-9 Retinal Therapeutics Market:

Product Market Share by Revenue - AMD Segment (U.S.), 2016 1-16

4-10 Retinal Therapeutics Market:

Product Market Share by Patients - AMD Segment (U.S.), 2016 1-17

4-11 Retinal Therapeutics Market:

Lucentis Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-21

4-12 Retinal Therapeutics Market:

Avastin Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-23

4-13 Retinal Therapeutics Market:

Iluvien Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-26

4-14 Retinal Therapeutics Market:

Ozurdex Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-28

4-15 Retinal Therapeutics Market:

Triamcinolone Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-30

4-16 Retinal Therapeutics Market:

Total DME Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-32

4-17 Retinal Therapeutics Market:

Product Market Share by Revenue - DME Segment (U.S.), 2016 1-33

4-18 Retinal Therapeutics Market:

Competitive Structure (U.S.), 2010 1-38

C h a p t e r 5

Appendix

5-1 Decision Support Database:

Total Population in Million (World), 2004-2014 1-1

5-2 Decision Support Database:

Population Aged 15 to 24 Years in Million (World), 2004-2014 1-4

5-3 Decision Support Database:

Population Aged 25 to 34 Years in Million (World), 2004-2014 1-6

5-4 Decision Support Database:

Population Aged 35 to 44 years in Million (World), 2004-2014 1-8

5-5 Decision Support Database:

Population Aged 45 to 54 Years in Million (World), 2004-2014 1-10

5-6 Decision Support Database:

Population Aged 55 to 64 Years in Million (World), 2004-2014 1-12

5-7 Decision Support Database:

Total Population 45 Plus in Million (World), 2004-2014 1-14

5-8 Decision Support Database:

Population 65 Plus in Million (World), 2004-2014 1-16

5-9 Decision Support Database:

AMD Population in '000 (World), 2002-2012 1-18

5-10 Decision Support Database:

New Cases of AMD in '000 (World), 2002-2012 1-20

5-11 Decision Support Database:

Prevalence of Diabetes in '000 (World), 2002-2012 1-22

5-12 Decision Support Database: New Cases of Diabetes in '000 (World), 2002-2012 1-25

List of Charts

C h a p t e r 2

Market Introduction

2.1 Retinal Therapeutics Market:

Market Segmentation by Disease (U.S.), 2009 1-2

2.2 Retinal Therapeutics Market:

Advanced Dry AMD and Intermediate AMD Prevalence Forecasts (U.S.), 2006-2016 1-6

2.3 Retinal Therapeutics Market:

Wet AMD Prevalence Forecast (U.S.), 2006-2016 1-8

2.4 Retinal Therapeutics Market:

Wet AMD Treated Patient Forecast (U.S.), 2006-2016 1-9

2.5 Retinal Therapeutics Market:

DR Prevalence among All Diabetics and among Type I Diabetics (U.S.), 2006-2016 1-11

2.6 Retinal Therapeutics Market:

Incidence and Treated Patient Forecasts for DME among Diagnosed Diabetics

(U.S.), 2006-2016 1-13

2.7 Retinal Therapeutics Market:

Prevalence Forecasts for BRVO, CRVO and Total RVO (U.S.) 2006-2016 1-14

2.8 Retinal Therapeutics Market:

Treatment-Eligible Patient Forecasts for BRVO, CRVO and Total RVO (U.S.), 2006-2016 1-16

2.9 Retinal Therapeutics Market:

Market Engineering Measurements (U.S.), 2009 1-17

C h a p t e r 4

Market Analysis

4.1 Retinal Therapeutics Market:

Visudyne Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-2

4.2 Retinal Therapeutics Market:

Macugen Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-4

4.3 Retinal Therapeutics Market:

Product Market Share by Revenue - AMD Segment (U.S.), 2009 1-6

4.4 Retinal Therapeutics Market:

Product Market Share by Patients - AMD Segment (U.S.), 2009 1-7

4.5 Retinal Therapeutics Market: VEGF Trap-Eye Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-11

4.6 Retinal Therapeutics Market: Lucentis Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-12

4.7 Retinal Therapeutics Market: Avastin Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-14

4.8 Retinal Therapeutics Market: Total AMD Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-15

4.9 Retinal Therapeutics Market: Product Market Share by

Revenue - AMD Segment (U.S.), 2016 1-16

4.10 Retinal Therapeutics Market: Product Market Share by

Patients - AMD Segment (U.S.), 2016 1-17

4.11 Retinal Therapeutics Market: Lucentis Revenue and Growth Rate

Forecasts - DME Segment (U.S.), 2006-2016 1-22

4.12 Retinal Therapeutics Market: Avastin Revenue and Growth Rate

Forecasts - DME Segment (U.S.), 2006-2016 1-23

4.13 Retinal Therapeutics Market: Iluvien Revenue and Growth Rate

Forecasts - DME Segment (U.S.), 2006-2016 1-27

4.14 Retinal Therapeutics Market:

Ozurdex Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-29

4.15 Retinal Therapeutics Market:

Triamcinolone Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-31

4.16 Retinal Therapeutics Market:

Total DME Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-32

4.17 Retinal Therapeutics Market:

Product Market Share by Revenue - DME Segment (U.S.), 2016 1-33

2-1

To order this report:

Machine Tool and Equipment Industry: U.S. Retinal Therapeutics Market

Machine Tool and Equipment Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Global CRO Market: Quantitative Assessment
2. Reportlinker Adds The Outlook for Medical Devices in North East Asia
3. Reportlinker Adds Global Microbiology Testing Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
4. Reportlinker Adds Endovascular Surgical Interventions: Technology Market Penetration and Roadmapping
5. Reportlinker Adds Global Hemostasis Diagnostics Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
6. Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers
7. Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers
8. Reportlinker Adds Top Medical Devices and Imaging Technologies 2011
9. Reportlinker Adds US Wound Closure Devices - Market Trend Till 2016
10. Reportlinker Adds UK CT Systems - Market Trend Till 2016
11. Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The global travel vaccines market to ... The report covers the present scenario and the growth prospects ... market size, the report considers the revenue generated from the sales ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering.  The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer ... our first franchise-wide Quack Gives Back initiative, and we’re very pleased ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading ... has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE ... Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage Lung ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... modes of access for customers and employees that are both engaging and easy ... with Service Smart Technology, the software company revealed today its plans to roll ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Vida ... raised an $18M Series B led by Canvas Ventures . Other investors include ... to scale its mobile platform to serve more consumers who are managing chronic ...
Breaking Medicine News(10 mins):